Positron Emission Tomography for Staging, and Treatment Assessment of Response in Lymphomas (the Pet-star Lymphoma Study)
It is currently unknown whether modifying treatment based on FDG-PET results is appropriate.
However, clinicians are increasingly using the FDG-PET result, where obtained, in deciding
management. Consequently, it would be premature to mandate PET-based treatment
modifications in this protocol. Patients will be treated with existing protocols at the
discretion of their treating oncologists, based on available information. Oncologists will
be surveyed as to whether FDG-PET scan results could have (or affect patient management, and
the intervention will be recorded).
Group A: Newly Diagnosed
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
To determine:the frequency in which the FDG-PET scan result will change the clinical management of the patient, and to record the intervention instituted within 3 months of the PET scan 2)early relapse rates for PET positive, and PET negative patients.
Richard Tsang, MD
University Health Network, Princess Margaret Hospital
Canada: Ethics Review Committee
UHN REB 07-0235-C